Breakthrough CRC Detection Method Unveiled at Digestive Disease Week 2024

Date:

Mainz Biomed N.V., a leading molecular genetics diagnostic company focused on early cancer detection, is set to unveil groundbreaking results from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. The study, conducted at 21 specialized gastroenterology sites in the US, enrolled 254 clinical patients and showcased the impressive performance of a multimodal screening test.

The presentation at DDW will highlight the test’s ability to analyze a combination of biomarkers, significantly improving early detection rates for colorectal cancer and precancerous conditions. By leveraging a unique approach that combines Fecal Immunochemical Test (FIT), DNA, mRNA biomarkers, and artificial intelligence (AI)/machine learning algorithms, Mainz Biomed aims to revolutionize current colorectal cancer screening practices and ultimately reduce cancer mortality rates globally.

The session, titled NOVEL STOOL-BASED NON-INVASIVE EARLY DETECTION OF COLORECTAL CANCER AND PRECANCEROUS LESIONS BY CLASSIC FIT COMBINED WITH NUCLEIC ACID-BASED BIOMARKER SIGNATURES, is sponsored by AGA and will be presented by Kammers, L on Sunday, May 19, 2024, from 12:30 PM to 1:30 PM EDT. The key findings from the eAArly DETECT study revealed a sensitivity of 97% for colorectal cancer and 82% for advanced adenoma, demonstrating the significant improvements made in both CRC and AA detection.

Mainz Biomed’s innovative approach underscores its commitment to advancing cancer detection and prevention, with the ultimate goal of decreasing colorectal cancer incidence and mortality rates worldwide. Stay tuned for the latest developments and insights from Mainz Biomed’s transformative research at DDW 2024.

See also  Progress of ChatGPT in Healthcare

Frequently Asked Questions (FAQs) Related to the Above News

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Advait Gupta
Advait Gupta
Advait is our expert writer and manager for the Artificial Intelligence category. His passion for AI research and its advancements drives him to deliver in-depth articles that explore the frontiers of this rapidly evolving field. Advait's articles delve into the latest breakthroughs, trends, and ethical considerations, keeping readers at the forefront of AI knowledge.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.